二肽基肽酶-4抑制剂的药学特点及临床应用

doi:10.6040/j.issn.1671-7554.0.2024.0174

摘要/Abstract

摘要： 糖尿病是当今威胁人类健康的常见疾病之一,导致巨大的社会经济负担。我国2型糖尿病患病率仍在上升,糖尿病的知晓率和控制率有所增加,但仍处于低水平。二肽基肽酶-4(dipeptidyl peptidase-4, DPP-4)抑制剂是新型上市的降糖药物,独特的作用机制满足了临床治疗对降糖药物的不同需求。然而,不同DPP-4抑制剂的药学特征、临床应用及安全性信息等方面存在差异,且在其他疾病领域的应用已逐步展开研究。本研究围绕我国已上市的DPP-4抑制剂的药学特征、临床应用、安全性信息、特殊情况用药及新型DPP-4抑制剂的研发进行讨论,协助临床合理选用DPP-4抑制剂。

关键词: 糖尿病, 二肽基肽酶-4抑制剂, 药学特点, 临床应用, 安全性

Abstract: Diabetes mellitus is a global public health problem, which leads to enormous human suffering. The prevalence of type 2 diabetes mellitus(T2DM)remains rising in China. Meanwhile, the awareness and control rate of diabetes have increased, but they are still at a low level. Dipeptidyl peptidase-4(DPP-4)inhibitors are novel oral antihyperglycemic agents. The unique mechanism of DPP-4 inhibitors satisfy different clinical demands. However, the molecular structure, clinical application and safety information of available DPP-4 inhibitors are different. We focus specially on the different clinical pharmaceutical characters, efficacy, safety and application on special population of DPP-4 inhibitors, which aims to provide the best drugs for individual patients.

Key words: Diabetes mellitus, Dipeptidyl peptidase-4 inhibitors, Pharmaceutical characteristics, Clinical application, Drug safety

中图分类号:

R587.1

林晓倩,封茂燕,牟正. 二肽基肽酶-4抑制剂的药学特点及临床应用[J]. 山东大学学报 (医学版), 2024, 62(12): 43-48.

LIN Xiaoqian, FENG Maoyan, MOU Zheng. Pharmaceutical characteristics and clinical utility of dipeptidyl peptidase-4 inhibitors[J]. Journal of Shandong University (Health Sciences), 2024, 62(12): 43-48.

参考文献

[1] Chen XW, He ZX, Zhou ZW, et al. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus[J]. Clin Exp Pharmacol Physiol, 2015, 42(12): 1225-1238.
[2] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020版)[J]. 中华糖尿病杂志, 2021, 13(4): 317-411. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China(2020 edition)[J]. Chin J Diabetes Mellitus, 2021, 13(4): 317-411.
[3] Sinclair A, Saeedi P, Kaundal A, et al. Diabetes and global ageing among 65-99-year-old adults: findings from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res Clin Pract, 2020, 162: 108078. doi:10.1016/j.diabres.2020.108078.
[4] Proença C, Ribeiro D, Freitas M, et al. A comprehensive review on the antidiabetic activity of flavonoids targeting PTP1B and DPP-4: a structure-activity relationship analysis[J]. Crit Rev Food Sci Nutr, 2022, 62(15): 4095-4151.
[5] Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review[J]. Ther Adv Drug Saf, 2014, 5(3): 138-146.
[6] 中国医师协会内分泌代谢科医师分会. DPP-4抑制剂临床应用专家共识[J]. 中华内分泌代谢杂志, 2018, 34(11): 899-903. Chinese Endocrinologist Association, Chinese Medical Doctor Association. Clinical application of DPP4 inhibitors: a Chinese expert consensus [J]. Chinese Journal of Endocrinology and Metabolism, 2018, 34(11): 899-903.
[7] Rummey C, Metz G. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site[J]. Proteins, 2007, 66(1): 160-171.
[8] Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences[J]. Drugs, 2011, 71(11): 1441-1467.
[9] 母义明, 朱大龙, 黄仲义. DPP-4抑制剂利格列汀的疗效与安全性评价[J]. 药品评价, 2016, 13(19): 19-27, 34. MU Yiming, ZHU Dalong, HUANG Zhongyi. Evaluation on clinical efficacy and safety of DPP-inhibitor linagliptin[J]. Drug Evaluation, 2016, 13(19): 19-27, 34.
[10] 陈莉明. 二肽基肽酶Ⅳ抑制剂类口服降糖药的药化性质和药理活性综合比较分析[J]. 中华糖尿病杂志, 2016, 8(8): 508-510.
[11] Feng J, Zhang ZY, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV[J]. J Med Chem, 2007, 50(10): 2297-2300.
[12] Sim AY, Barua S, Kim JY, et al. Role of DPP-4 and SGLT2 inhibitors connected to alzheimer disease in type 2 diabetes mellitus[J]. Front Neurosci, 2021, 15: 708547. doi:10.3389/fnins.2021.708547.
[13] de Monte SM. Type 3 diabetes is sporadic Alzheimers disease: mini-review[J]. Eur Neuropsychopharmacol, 2014, 24(12): 1954-1960.
[14] Chen SY, Zhou M, Sun J, et al. DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling[J]. Neuropharmacology, 2019, 157: 107668. doi:10.1016/j.neuropharm.2019.107668.
[15] Ide M, Sonoda N, Inoue T, et al. The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation[J]. PLoS One, 2020, 15(2): e0228750. doi:10.1371/journal.pone.0228750.
[16] Zeng XD, Li XH, Chen ZB, et al. DPP-4 inhibitor saxagliptin ameliorates oxygen deprivation/reoxygenation-induced brain endothelial injury[J]. Am J Transl Res, 2019, 11(10): 6316-6325.
[17] Pham TK, Nguyen THT, Yi JM, et al. Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice[J]. Exp Mol Med, 2023, 55(4): 767-778.
[18] Akashi N, Umemoto T, Yamada H, et al. Teneligliptin, a DPP-4 inhibitor, improves vascular endothelial function via divergent actions including changes in circulating endothelial progenitor cells[J]. Diabetes Metab Syndr Obes, 2023, 16: 1043-1054. doi:10.2147/DMSO.S403125.
[19] Lee JM, Yoo IK, Lee JM, et al. Dipeptidyl-peptidase-4(DPP-4)inhibitor ameliorates 5-flurouracil induced intestinal mucositis[J]. BMC Cancer, 2019, 19(1): 1016.
[20] Olivares M, Neyrinck AM, Pötgens SA, et al. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice[J]. Diabetologia, 2018, 61(8): 1838-1848.
[21] Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors[J]. Clin Pharmacokinet, 2012, 51(8): 501-514.
[22] Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J]. N Engl J Med, 2013, 369(14): 1317-1326.
[23] Alshamrani AA, Al-Hamamah MA, Albekairi NA, et al. Impacts of the DPP-4 inhibitor saxagliptin and SGLT-2 inhibitor dapagliflozin on the gonads of diabetic mice[J]. Biomedicines, 2023, 11(10): 2674.
[24] Kim SH, Jung E, Yoon MK, et al. Pharmacological profiles of gemigliptin(LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo[J]. Eur J Pharmacol, 2016, 5(788): 54-64.
[25] Jain MR, Joharapurkar AA, Kshirsagar SG, et al. ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of type 2 diabetes mellitus[J]. Br J Pharmacol, 2017, 174(14): 2346-2357.
[26] Wang L, Li XP, Kong Y, et al. Pharmacokinetics, tissue distribution and excretion of compound 6c, a novel DPP-4 inhibitor, following intragastric administration in rats by ultra-performance liquid chromatography-tandem mass spectrometry[J]. Eur J Pharm Sci, 2022, 173: 106162. doi:10.1016/j.ejps.2022.106162.

相关文章 15

[1]	杜学识,倪向敏,梁馨予,白倩,朱文艺,王建. 雌马酚对DN的保护作用及潜在靶点[J]. 山东大学学报 (医学版), 2024, 62(8): 49-58.
[2]	孙晓丹,杨创. 多黏菌素B治疗ICU耐碳青霉烯类革兰阴性杆菌感染患者的效果[J]. 山东大学学报 (医学版), 2024, 62(7): 72-77.
[3]	许沛晨,李晓博,庄向华,娄能俊,吕丽,周玲雁,牟亚朋,宋玉文,陈诗鸿. 儿童Alstrom综合征2例并文献复习[J]. 山东大学学报 (医学版), 2024, 62(3): 107-111.
[4]	于丹凤,曹娟,于世佳,杜鲁涛,侯新国. 电化学发光法与液相色谱-串联质谱法评估糖尿病患者维生素D缺乏程度的效能比较与界值确定[J]. 山东大学学报 (医学版), 2023, 61(7): 90-95.
[5]	李金泉,高美芳,闫飞,董明. 136例2型糖尿病患者肌肉痉挛的发生频率及危险因素[J]. 山东大学学报 (医学版), 2023, 61(5): 20-24.
[6]	张天鑫,张婷,黄鑫,韩佳沂,王淑康. 氨基酸与2型糖尿病因果关系的孟德尔随机化分析[J]. 山东大学学报 (医学版), 2023, 61(5): 102-107.
[7]	黄珊,娄能俊,韩晓琳,梁中昊,华梦羽,庄向华,陈诗鸿. 高糖环境下Lipin1对神经元代谢组学的影响[J]. 山东大学学报 (医学版), 2023, 61(2): 1-8.
[8]	钱明,姜雷,王学建,赵伟,汪志峰,张毅. 神经内镜与钻孔引流治疗大量慢性硬膜下血肿的疗效及安全性[J]. 山东大学学报 (医学版), 2023, 61(12): 94-99.
[9]	包瑾瑾,刘庆燕,孙甜甜,陈青,刘佳. 糖尿病相关抗体阳性合并MODY14相关APPL1基因突变1例[J]. 山东大学学报 (医学版), 2023, 61(12): 113-118.
[10]	韩梅,孟维静,陶子琨,杨希,徐雅琪,穆华夏,卜伟晓,王素珍,石福艳. 基于G-计算的高血压、抑郁在2型糖尿病与认知功能之间的因果多中介分析[J]. 山东大学学报 (医学版), 2023, 61(10): 101-108.
[11]	宋宜耘,于慧,高兆丽,李宪花. 基于SIRT1/PGC-1α通路探讨葡萄籽原花青素提取物对糖尿病肾脏疾病大鼠的保护作用[J]. 山东大学学报 (医学版), 2023, 61(1): 1-9.
[12]	马翔,赵飞燕. 。卵子冷冻保存现状与进展[J]. 山东大学学报 (医学版), 2022, 60(9): 19-23.
[13]	李涛,杨春林,杜通,李亨,王聪聪,李晓丽,段瑞生,张蓬. 糖尿病对重症肌无力NK细胞亚型及功能的影响[J]. 山东大学学报 (医学版), 2022, 60(5): 31-36.
[14]	唐钦连,张玉超,赵蕙琛,马小莉,于民民,刘元涛. 携带成对盒4基因突变早发糖尿病1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(5): 104-108.
[15]	赵美茹,朱迪,刘淋,管庆波,张栩. 简易胰岛素抵抗指标与698例2型糖尿病患者发生高尿酸血症风险的关联[J]. 山东大学学报 (医学版), 2022, 60(12): 44-51.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed